Cargando…

Management of Kawasaki disease

Kawasaki disease (KD) is an acute self-limiting inflammatory disorder, associated with vasculitis, affecting predominantly medium-sized arteries, particularly the coronary arteries. In developed countries KD is the commonest cause of acquired heart disease in childhood. The aetiology of KD remains u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eleftheriou, D, Levin, M, Shingadia, D, Tulloh, R, Klein, NJ, Brogan, PA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888612/ https://www.ncbi.nlm.nih.gov/pubmed/24162006 http://dx.doi.org/10.1136/archdischild-2012-302841

Ejemplares similares

Cardiovascular status after Kawasaki disease in the UK
por: Shah, V, et al.
Publicado: (2015)

Lifetime cardiovascular management of patients with previous Kawasaki disease
por: Brogan, Paul, et al.
Publicado: (2020)

Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report
por: Brogan, Robert J, et al.
Publicado: (2009)

Circulating endothelial cells and endothelial progenitor cells in childhood primary angiitis of the central nervous system
por: Eleftheriou, D, et al.
Publicado: (2008)

Inflammatory lesions of the orbit: a single paediatric rheumatology centre experience
por: Boulter, EL, et al.
Publicado: (2011)

PReS-FINAL-2363: Behçet's disease in children: the Great Ormond Street Hospital experience
por: Nanthapisal, S, et al.
Publicado: (2013)

9.3 Endothelial progenitor cells and vasculogenic responses to therapy in children with primary systemic vasculitis
por: Clarke, LA, et al.
Publicado: (2008)

Behaviour sequelae following acute Kawasaki disease
por: Carlton-Conway, Daniel, et al.
Publicado: (2005)

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol
por: Eleftheriou, Despina, et al.
Publicado: (2023)

Giant coronary artery aneurysms in a 12-week-old infant with incomplete Kawasaki disease
por: Guile, Lucy, et al.
Publicado: (2018)

Dissecting Kawasaki disease: a state-of-the-art review
por: Dietz, S. M., et al.
Publicado: (2017)

Controversies in diagnosis and management of Kawasaki disease
por: Pilania, Rakesh Kumar, et al.
Publicado: (2018)

Kawasaki Disease: Pathology, Risks, and Management
por: Seki, Mitsuru, et al.
Publicado: (2022)

Vasculitis update: pathogenesis and biomarkers
por: Brogan, Paul, et al.
Publicado: (2017)

Management of sequelae of Kawasaki disease in adults
por: Gordon, John B., et al.
Publicado: (2017)

Refractory Kawasaki disease: diagnostic and management challenges
por: Duignan, Sophie, et al.
Publicado: (2019)

Therapeutic advances in the treatment of vasculitis
por: Eleftheriou, Despina, et al.
Publicado: (2016)

Kawasaki disease
por: Kawasaki, Tomisaku
Publicado: (2006)

Monogenic polyarteritis nodosa caused by ADA2 Deficiency: the GOSH experience
por: Nanthapisal, S, et al.
Publicado: (2015)

Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease
por: Condliffe, R., et al.
Publicado: (2018)

Kawasaki Disease
por: Baltimore, Robert S.
Publicado: (1988)

Kawasaki Disease
por: Kim, Dong Soo
Publicado: (2006)

B Cells and Antibodies in Kawasaki Disease
por: Lindquist, Michael E., et al.
Publicado: (2019)

Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic
por: Harahsheh, Ashraf S., et al.
Publicado: (2020)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

Small vessel vasculitis
por: Brogan, Paul, et al.
Publicado: (2009)

Epidemiology and disease burden of tuberculosis in children: a global perspective
por: Seddon, James A, et al.
Publicado: (2014)

Kawasaki Disease: The Role of Immune Complexes Revisited
por: Menikou, Stephanie, et al.
Publicado: (2019)

Paediatric Behçet’s disease: a UK tertiary centre experience
por: Nanthapisal, Sira, et al.
Publicado: (2016)

Kawasaki disease in infants
por: Yeom, Jung Sook, et al.
Publicado: (2013)

Kawasaki disease for dermatologists
por: Gupta, Aman, et al.
Publicado: (2016)

Kawasaki Disease and COVID-19
por: Gkoutzourelas, Athanasios, et al.
Publicado: (2020)

PReS-FINAL-2187: Use of screening tests in patients presenting to paediatric rheumatology with suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome
por: Cruikshank, M, et al.
Publicado: (2013)

Medium-size-vessel vasculitis
por: Dillon, Michael J., et al.
Publicado: (2009)

Kawasaki Disease
por: Yeung, Rae S. M.
Publicado: (2012)

Diagnosis of incomplete Kawasaki disease
por: Yu, Jeong Jin
Publicado: (2012)

Recent Advances in Kawasaki Disease
por: Kim, Kyu Yeun, et al.
Publicado: (2016)

Reality of Kawasaki disease epidemiology
por: Kim, Gi Beom
Publicado: (2019)

Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease
por: Marchesi, Alessandra, et al.
Publicado: (2021)

Impaired function of endothelial progenitor cells in children with primary systemic vasculitis
por: Hong, Ying, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_furp3bjdohihv195oeqg7ndpo6